- It's a good news/ bad news type of day for Nektar Therapeutics (NKTR), although it's safe to say investors will be taking a "glass is half empty" view during today's session.
- The bad news is that the stock is down 20% premarket after NKTR-181 missed its primary endpoint in a Phase 2 trial. (More on this here)
- The good news is that the EMA has accepted AstraZeneca's (AZN) MAA for naloxegol triggering a $25M milestone payment to NKTR.
Nektar dives on Phase 2 miss, naloxegol MAA triggers milestone payment
Sep 27 2013, 08:10 ET